Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
Launched by UNIVERSITY OF WISCONSIN, MADISON · Nov 2, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Using Novel Imaging to More Safely Treat Neuroendocrine Tumors," is exploring a new imaging technique called DetectnetTM PET/CT. The goal is to see if this advanced imaging can help make a specific treatment, Lutathera, safer for patients with neuroendocrine tumors, which are a type of cancer that affects hormone-producing cells.
To participate, individuals need to be between the ages of 65 to 74 and must be eligible for Lutathera treatment. The trial involves two phases with a total of six visits, during which participants will undergo additional imaging scans. It's important to note that those who cannot lie flat for the scans or have known issues with the imaging methods will not be eligible. If you or a loved one is considering this trial, it could offer a chance to contribute to important research while accessing new imaging technology that may improve treatment safety.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Candidates for 177Lu-DOTATATE (Lutathera) treatment for somatostatin receptor-positive neuroendocrine tumor
- Exclusion Criteria:
- • Unable to lie flat during or tolerate PET/CT or SPECT/CT
- • Known incompatibility to CT. SPECT, or PET scans
- • Unlikely to comply with study procedures, restrictions and requirements and judged by the investigator that the participant is not suitable for participation in the study
About University Of Wisconsin, Madison
The University of Wisconsin-Madison is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive resources, including cutting-edge facilities and a diverse pool of expert researchers, to conduct rigorous studies that address critical health challenges. The institution's focus on translating research findings into practical applications fosters the development of new treatments and interventions, ultimately contributing to improved patient outcomes and public health initiatives. As a sponsor of clinical trials, the University of Wisconsin-Madison is dedicated to upholding the highest ethical standards and ensuring participant safety throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madison, Wisconsin, United States
Patients applied
Trial Officials
Steve Cho, MD
Principal Investigator
University of Wisconsin, Madison
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported